Nightstar has added a licence for a potential treatment of Stargardt disease to its portfolio.
Nightstar Therapeutics, a UK-based retina-focused gene therapy spinout of University of Oxford, licensed a proof-of-concept yesterday from the university’s tech transfer office Oxford University Innovation.
The proof-of-concept seeks to tackle Stargardt disease, a currently untreatable condition that causes progressive vision loss and often blindness. The therapy targets an inherited gene called ABCA4 responsible for damaging photoreceptor cells towards the centre of the retina.
Nightstar hopes to utilise the clinical experience gained elsewhere in its portfolio to expedite development of the…
